Cimzia (certolizumab pegol) / Astellas, UCB 
Welcome,         Profile    Billing    Logout  
 50 Diseases   29 Trials   29 Trials   3299 News 


«12...2223242526272829303132...3839»
  • ||||||||||  DOES FECAL DIVERSION INDUCE A CLINICAL RESPONSE TO CROHNS DISEASE OF THE COLORECTUM? () -  May 4, 2020 - Abstract #DDW2020DDW_4204;    
    This largest report in the biologic era of fecal diversion for medically refractory CD proctocolitis or perianal disease showed that only 33% of patients achieved a clinical response. Biologic use before fecal diversion and diversion for proctocolitis with perianal disease was associated with a significantly lower clinical response suggesting that the worse the disease, the lower the chance of response.
  • ||||||||||  Movicol (AJG555) / Mochida, Eisai, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    Journal:  Polyethylene glycol: an underrecognized compound in certolizumab pegol and Movicol that may cause anaphylaxis. (Pubmed Central) -  Apr 30, 2020   
    In patients with moderate-to-severe RA, sarilumab 200 mg SC every 2 weeks + methotrexate can be considered a cost-effective treatment option, with lower costs and greater health benefits than alternative treatment sequences (+ methotrexate) beginning with adalimumab, certolizumab, golimumab and tofacitinib and below commonly accepted cost-effectiveness thresholds against tocilizumab + methotrexate or csDMARD active treatment. No abstract available
  • ||||||||||  Journal:  The use of biologics for uveitis associated with spondyloarthritis. (Pubmed Central) -  Apr 29, 2020   
    No abstract available In cases of uveitis that require long-term control, biologics are an emerging and valuable class of medications for these patients, and may provide avenues to control both their underlying SpA and uveitis manifestations.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date:  Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) -  Apr 29, 2020   
    P3,  N=163, Active, not recruiting, 
    In cases of uveitis that require long-term control, biologics are an emerging and valuable class of medications for these patients, and may provide avenues to control both their underlying SpA and uveitis manifestations. Trial completion date: Jan 2022 --> Jun 2023 | Trial primary completion date: Oct 2021 --> Jun 2023
  • ||||||||||  Review, Journal, Adverse events:  A review of ocular adverse events of biological anti-TNF drugs. (Pubmed Central) -  Apr 28, 2020   
    We found a variety of data associating new onset of uveitis with anti-TNF therapy for rheumatic conditions, predominantly under etanercept.In conclusion, although there is increasing data on ocular adverse events, it remains to be seen whether the suggested link between TNF inhibitors and the onset of ocular inflammation is substantiated by more quality data. Nevertheless, the awareness of potential treatment side effects with anti-TNF should be highlighted.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) -  Apr 27, 2020   
    P1,  N=30, Active, not recruiting, 
    Nevertheless, the awareness of potential treatment side effects with anti-TNF should be highlighted. Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
  • ||||||||||  Review, Journal:  Desensitization to biological agents used in rheumatology. (Pubmed Central) -  Apr 25, 2020   
    Drug desensitization is a new issue in rheumatology, and the solution to the problem of allergic reactions to biological drugs, which gives patients with rheumatic diseases the opportunity to extend and prolong their therapy. The present article is one of the first widely discussing this topic in the biological treatment of rheumatic diseases.
  • ||||||||||  Clinical, Review, Journal:  Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. (Pubmed Central) -  Apr 22, 2020   
    Randomised trials provide Moderate Quality Evidence for a favourable benefit-harm balance supporting concomitant use of MTX rather than monotherapy when prescribing a biological agent in patients with RA although in absolute terms only 7-16 more out of 100 patients will achieve an ACR50 response after 6 months of this combination therapy. Available evidence suggests the efficacy and safety of IFX in pulmonary, cutaneous, ocular, neurologic, and multisystem sarcoidosis, and ADA in cutaneous and ocular sarcoidosis.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    Clinical, Journal:  A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. (Pubmed Central) -  Apr 10, 2020   
    In this population-based study of rheumatic disease patients from a high incident area, TNF inhibitor exposure was associated with an 18-time increased TB incidence. Adalimumab and certolizumab were associated with greater and earlier TB diagnosis compared to etanercept.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    Journal:  The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation. (Pubmed Central) -  Apr 4, 2020   
    Anti-certolizumab antibodies were detected in a large proportion of patients, but in most cases where ADAs were detected, certolizumab was also present in high concentrations, directly correlating with in vitro neutralising capacity. These results indicate that measurement of certolizumab drug levels, rather than ADAs, have direct clinical significance.
  • ||||||||||  Trial suspension, Checkpoint inhibition:  TICIMEL: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (clinicaltrials.gov) -  Apr 1, 2020   
    P1,  N=30, Suspended, 
    Among patients with RA who had previously received ≥ 1 bDMARD, tocilizumab-treated patients exhibited a similar or significantly better biologic persistence than those receiving other bDMARDs. Recruiting --> Suspended
  • ||||||||||  Journal:  Nonadherence to Biologic Therapies in Inflammatory Bowel Disease. (Pubmed Central) -  Mar 31, 2020   
    Younger age and noncommercial insurance also were associated with biologic nonadherence. Modality of administration should be taken into account when selecting a biologic agent for treatment of IBD.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    Review, Journal:  Management of psoriasis in pregnancy - a review of the evidence to date. (Pubmed Central) -  Mar 24, 2020   
    Within biological therapies, certolizumab pegol has recently been identified as a promising approach during pregnancy because it has been shown to have no late active placental transfer and no clear signs of foetal harm. This article aims to review the impact of psoriasis during pregnancy, how the disease can be managed pharmacologically during this period according to the available armamentarium, and the possible effects of the therapeutic options for the mother and the foetus.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date:  PreCePRA: Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain (clinicaltrials.gov) -  Mar 10, 2020   
    P3,  N=156, Completed, 
    No unexpected or new safety signals were identified when neutralising IL-17A and IL-17F in patients with RA concomitantly treated with CZP, but the rate of TEAEs was higher with dual inhibition. Trial completion date: Jun 2019 --> Jan 2020
  • ||||||||||  Biomarker, Trial completion date, Trial primary completion date:  RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) -  Mar 10, 2020   
    P4,  N=110, Recruiting, 
    Trial completion date: Jun 2019 --> Jan 2020 Trial completion date: Sep 2019 --> Dec 2020 | Trial primary completion date: Jul 2019 --> Dec 2020
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] THE EFFECTS OF WHITE AND BROWN BAGGING OF PHYSICIAN-ADMINISTERED DRUGS ON SPENDING AND OUT-OF-POCKET COSTS IN MEDICARE () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_119;    
    For beneficiaries who did not receive the low-income subsidy, median out-of-pocket spending when comparing Part D out-of-pocket costs to the 20% co-pay for Part B ranged from $5 lower for denosumab to $5,563 lower for eculizumab; however, beneficiaries may have supplemental insurance that would reduce their Part B out-of-pocket costs. For beneficiaries who receive physician-administered drugs, selecting a Part D plan with a low co-pay for their drug regimen can offer savings compared to the 20% Part B co-insurance; however, white/brown-bagging places burden on beneficiaries to transport their drugs to an infusion center and may increase program spending.